Evidence map›Paper›PMID 38614278›Full record

Trial reportInternational journal of radiation oncology, biology, physics2024

Prospective Trial of Functional Lung Avoidance Radiation Therapy for Lung Cancer: Quality of Life Report.

Joseph Lombardo, Edward Castillo, Richard Castillo, Ryan Miller, Bernard Jones, Moyed Miften, Brian Kavanagh, Adam Dicker, Cullen Boyle, Benjamin Leiby and 7 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in International journal of radiation oncology, biology, physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07312682 (Clinical Study on 4DCT-Based Pulmonary Ventilation Imaging for Functional Lung Avoidance in Radiotherapy of Lung Cancer), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07312682 active not recruitingnot on this map

Clinical Study on 4DCT-Based Pulmonary Ventilation Imaging for Functional Lung Avoidance in Radiotherapy of Lung Cancer

TypeobservationalSponsorThe Second Affiliated Hospital of Chongqing Medical UniversityRan2024 to 2026Enrolled202ConditionsLung Neoplasms, Radiation Pneumonitis
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Joseph LombardoThomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania.
Edward CastilloUT Austin, Department of Biomedical Engineering, Austin, Texas.
Richard CastilloEmory University School of Medicine, Radiation Oncology, Atlanta, Georgia.
Ryan MillerThomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania.
Bernard JonesUniversity of Colorado, Radiation Oncology, Denver, Colorado.
Moyed MiftenUniversity of Colorado, Radiation Oncology, Denver, Colorado.
Brian KavanaghUniversity of Colorado, Radiation Oncology, Denver, Colorado.
Adam DickerThomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania.
Cullen BoyleThomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania.
Benjamin LeibyThomas Jefferson University, Department of Pharmacology, Physiology, and Cancer Biology, Philadelphia, Pennsylvania.
Joshua BanksThomas Jefferson University, Department of Pharmacology, Physiology, and Cancer Biology, Philadelphia, Pennsylvania.
Nicole L SimoneThomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania.
Benjamin MovsasHenry Ford Cancer Institute, Radiation Oncology, Detroit, Michigan.
Inga GrillsBeaumont Health, Radiation Oncology, Royal Oak, Michigan.
Thomas GuerreroUC San Diego, Radiation Oncology, San Diego, California.
Chad G RusthovenUniversity of Colorado, Radiation Oncology, Denver, Colorado.
Yevgeniy VinogradskiyThomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania. Electronic address: Yevgeniy.vinogradskiy@jefferson.edu.
Thomas Jefferson University · USUniversity of Colorado Denver · USBeaumont Health · USEmory University · USThe University of Texas at Austin · USUniversity of California, San Diego · US

Funding

Mechanism of lung cancer resistance to tyrosine kinase inhibitor and radiation treatmentsR01CA232587 · NCI · UNIVERSITY OF IOWA · PI SIMONE, NICOLE L · 2018 to 2022
$2.9M
Development of a Novel Lung Function Imaging Modality for comprehensive management of lung cancerR01CA236857 · NCI · UNIVERSITY OF COLORADO DENVER · PI CASTILLO, EDWARD, CASTILLO, RICHARD · 2020 to 2025
$2.4M
Quantitative Lung Function Imaging to Reduce Toxicity for patients treated with Radiation and ImmunotherapyUH3CA247605 · NCI · THOMAS JEFFERSON UNIVERSITY · PI CASTILLO, EDWARD, CASTILLO, RICHARD · 2023 to 2025
$1.1M
Quantitative Lung Function Imaging to Reduce Toxicity for patients treated with Radiation and ImmunotherapyUG3CA247605 · NCI · THOMAS JEFFERSON UNIVERSITY · PI CASTILLO, EDWARD, CASTILLO, RICHARD · 2021 to 2022
$664k
NCI NIH HHS R01 CA232587NCI NIH HHS R01 CA236857NCI NIH HHS UG3 CA247605NCI NIH HHS UH3 CA247605
6 · The paper itself

Abstract

purposeA novel form of lung function imaging has been developed that uses 4-dimensional computed tomography (4DCT) data to generate lung ventilation images (4DCT-ventilation). Functional avoidance uses 4DCT-ventilation to reduce doses to functional lung with the aim of reducing pulmonary side effects. A phase 2, multicenter 4DCT-ventilation functional avoidance clinical trial was completed. The purpose of this work was to quantify changes in patient-reported outcomes (PROs) for patients treated with functional avoidance and determine which metrics are predictive of PRO changes. MATERIALS AND

methodsPatients with locally advanced lung cancer receiving curative-intent radiation therapy were accrued. Each patient had a 4DCT-ventilation image generated using 4DCT data and image processing. PRO instruments included the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire administered pretreatment; at the end of treatment; and at 3, 6, and 12 months posttreatment. Using the FACT-Trial Outcome Index and the FACT-Lung Cancer Subscale results, the percentage of clinically meaningful declines (CMDs) were determined. A linear mixed-effects model was used to determine which patient, clinical, dose, and dose-function metrics were predictive of PRO decline.

resultsOf the 59 patients who completed baseline PRO surveys. 83% had non-small cell lung cancer, with 75% having stage 3 disease. The median dose was 60 Gy in 30 fractions. CMD FACT-Trial Outcome Index decline was 46.3%, 38.5%, and 26.8%, at 3, 6, and 12 months, respectively. CMD FACT-Lung Cancer Subscale decline was 33.3%, 33.3%, and 29.3%, at 3, 6, and 12 months, respectively. Although an increase in most dose and dose-function parameters was associated with a modest decline in PROs, none of the results were significant (all P > .053).

conclusionsThe current work presents an innovative combination of use of functional avoidance and PRO assessment and is the first report of PROs for patients treated with prospective 4DCT-ventilation functional avoidance. Approximately 30% of patients had clinically significant decline in PROs at 12 months posttreatment. The study provides additional data on outcomes with 4DCT-ventilation functional avoidance.

Indexed as

Four-Dimensional Computed TomographyLung NeoplasmsPatient Reported Outcome MeasuresQuality of LifeAgedAged, 80 and overCarcinoma, Non-Small-Cell LungFemaleHumansLungMaleMiddle AgedProspective Studies

Identifiers

PMID38614278
PMCPMC11381170
OpenAlexW4394796338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.